Trial for PF-07321332 for children at risk from COVID-19
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial studies whether PF-07321332 (with ritonavir) helps children under 18 who have COVID-19 at home but are at high risk of severe illness. It looks at whether starting treatment early can reduce progression to worse disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are under 18 years old (and can take the study medicine if swallowing is required)
- COVID-19 was confirmed by testing within the last 72 hours
- Symptoms started within the last 5 days, and at least one COVID-19 symptom is present
- The child has a medical condition that increases risk for severe COVID-19
- The child is not currently hospitalized and does not need hospital treatment for COVID-19
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how well an antiviral works in the body when started early in people with COVID-19 symptoms. You may be able to join if you’re an otherwise healthy adult with confirmed infection and symptoms for less than 4 days.
This trial tests a new drug, ratutrelvir, for people with mild to moderate COVID-19. It aims to find a safe and effective dose to help you feel better faster.
This study tests an experimental oral antiviral, secutrelvir, for people with mild to moderate COVID-19 who are not sick enough to need hospital care. The medicine aims to reduce symptoms and help you recover faster.
This trial studies a longer course of remdesivir combined with nirmatrelvir/ritonavir (Paxlovid) for immunocompromised patients who have persistent COVID-19. The goal is to see if this combination helps clear the virus better.
This study tests a new antibody medicine for people with COVID-19 who are at high risk of getting very sick. If you qualify, you would receive the study drug or a placebo (inactive substance) to see if it helps you recover without needing to go to the hospital.
This trial tests whether Codivir can help people hospitalized with moderate COVID-19 recover better than a placebo (inactive pill). It will compare outcomes while participants receive standard hospital care.
Hear when a new COVID-19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.